Based on the tumor-promoting role of HuR in the TME, various RBP-TME CRC therapeutic compounds have been developed, including small molecule inhibitors (such as antisense oligonucleotides (ASOs)), gene manipulation, targeted delivery of Small interfering RNA (siRNA), agonists, and tumor vaccines (12, 21), providing a cutting-edge perspective for the clinical treatment of CRC. The gene discussed is ELAVL1; the disease is colorectal carcinoma.